{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-009384","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.158827+00:00","generated_at":"2026-05-27T02:25:20.595843+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Collegium expands board, appoints Nancy Lurker as new director","bullets":["Board expanded from 8 to 9 directors; Nancy Lurker appointed effective Feb 4, 2025.","Lurker, 67, former CEO of EyePoint Pharmaceuticals, currently vice chair of EyePoint board.","She will receive annual cash retainer of $50,000 (prorated) and equity award of $412,500 in RSUs vesting over 1 year.","Board determined Lurker is independent under Nasdaq rules; no related party transactions.","She also serves on boards of Alkermes (ALKS), Altasciences, and National Sanitation Foundation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-009384","json":"https://secwatch.observer/filing/0001104659-25-009384.json","markdown":"https://secwatch.observer/filing/0001104659-25-009384.md","text":"https://secwatch.observer/filing/0001104659-25-009384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/tm255440d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T02:25:20.595843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e36ada91e","claim":"Nancy Lurker was appointed as Director at COLLEGIUM PHARMACEUTICAL, INC.","evidence_excerpt":"approved the expansion of the Board from eight directors to nine directors and the appointment of Nancy Lurker to serve as a director of the Board, effective as of February 4, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925009384/0001104659-25-009384-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}